Participants received either semaglutide 2.4 mg weekly or placebo, combined with lifestyle intervention, for 68 weeks
Weeks 13 and beyond: full therapeutic effect At 12mg weekly maintenance, you are at the dose that produced the headlines
"GLP-1 receptor agonists act to reduce insulin resistance by increasing glucose transporters, which in turn decreases inflammation, reduces oxidative stress, promotes insulin secretion, slows gastric emptying, and inhibits macrophage secretion of inflammatory cytokines." Mia Hudanich, Nova Southeastern University One study spanning 26 weeks revealed that a daily dose of 1.8 mg liraglutide reduced visceral adipose tissue (VAT) by 18%
On average, patients lose 10-20% of their body weight over a 6-12 month period with consistent GLP-1 treatment
Wegovy is approved for people with a BMI of 30 or higher, or 27+ if theres a related health condition like high blood pressure, PCOS, insulin resistance, or sleep apnoea